Cellerant – About the Company
Cellerant is a private biotechnology company developing novel treatments for oncology and hematologic conditions. Lead candidate CLT-008, an off-the shelf, cryopreserved cell replacement therapy, is expected to enter a Phase II trial in the fourth quarter of 2014 for the treatment of severe neutropenia in acute myeloid leukemia (AML) patients. The trial is funded through $191.6 million in BARDA contracts awarded to date for CLT-008’s application in acute radiation syndrome (ARS). The Company also has a robust platform to identify novel targets and antibodies against cancer stem cell (CSC), with the first IND expected in 2016.